Published in BMJ on January 06, 2001
Effects of disease modifying agents and dietary intervention on insulin resistance and dyslipidemia in inflammatory arthritis: a pilot study. Arthritis Res (2002) 0.95
Prediction of calculated future cardiovascular disease by monocyte count in an asymptomatic population. Vasc Health Risk Manag (2008) 0.91
A Study of Association of Ankle Brachial Index (ABI) and the Highly Sensitive C - Reactive Protein (hsCRP) in Type 2 Diabetic Patients and in Normal Subjects. J Clin Diagn Res (2012) 0.84
Urinalysis for interleukin-8 in the non-invasive diagnosis of acute and chronic inflammatory diseases. Postgrad Med J (2003) 0.81
C-reactive protein and lipid profiles in Korean patients with normal tension glaucoma. Korean J Ophthalmol (2009) 0.76
C reactive protein and acute phase of ischaemic stroke. BMJ (2001) 0.75
Predictive role of high sensitive C-reactive protein in early onset mortality after ischemic stroke. Iran J Neurol (2012) 0.75
The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med (1994) 8.10
C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol (1999) 7.15
Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ (2000) 6.10
Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation (1999) 3.90
C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood (1993) 2.48
C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction. J Exp Med (1999) 2.17
Coronary C-reactive protein distribution: its relation to development of atherosclerosis. Atherosclerosis (1999) 1.96
C-reactive protein colocalizes with complement in human hearts during acute myocardial infarction. Circulation (1997) 1.94
Complement and atherogenesis: binding of CRP to degraded, nonoxidized LDL enhances complement activation. Arterioscler Thromb Vasc Biol (1999) 1.86
Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty. J Am Coll Cardiol (1999) 1.33
On the size of the active site in proteases. I. Papain. Biochem Biophys Res Commun (1967) 18.32
The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med (1994) 8.10
Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein. Adv Immunol (1983) 7.47
Common core structure of amyloid fibrils by synchrotron X-ray diffraction. J Mol Biol (1997) 7.27
Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ (2000) 6.10
C-reactive protein fifty years on. Lancet (1981) 5.93
Maturation of the immune response in germinal centers. Cell (1991) 5.68
Why doesn't audit work? BMJ (1998) 5.63
Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis. Nature (1997) 5.47
Particulate air pollution is associated with an acute phase response in men; results from the MONICA-Augsburg Study. Eur Heart J (2001) 4.21
Private company wins rights to Icelandic gene database. BMJ (1999) 4.04
Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity. Nat Med (1999) 3.88
Mapping the active site of papain with the aid of peptide substrates and inhibitors. Philos Trans R Soc Lond B Biol Sci (1970) 3.29
Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component. N Engl J Med (1990) 3.17
On the active site of proteases. 3. Mapping the active site of papain; specific peptide inhibitors of papain. Biochem Biophys Res Commun (1968) 3.10
Comparative clinical study of protein SAP (amyloid P component) and C-reactive protein in serum. Clin Exp Immunol (1978) 3.06
Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease. J Clin Invest (1993) 2.92
Role of complement in induction of the allergic response. Nat New Biol (1972) 2.90
Solid phase radioimmunoassays for human C-reactive protein. Clin Chim Acta (1981) 2.77
Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet (2001) 2.71
Activation of mouse complement by different classes of mouse antibody. Immunology (1979) 2.68
The physiological structure of human C-reactive protein and its complex with phosphocholine. Structure (1999) 2.64
Association between C-reactive protein and features of the metabolic syndrome: a population-based study. Diabetes Care (2000) 2.63
Effect of alcohol consumption on systemic markers of inflammation. Lancet (2001) 2.52
Serum amyloid P-component is an acute-phase reactant in the mouse. Nature (1979) 2.49
Complement dependence of localisation of aggregated IgG in germinal centres. Scand J Immunol (1975) 2.48
Serum levels of C-reactive protein in Crohn's disease and ulcerative colitis. Eur J Clin Invest (1982) 2.48
Role of complement in induction of antibody production in vivo. Effect of cobra factor and other C3-reactive agents on thymus-dependent and thymus-independent antibody responses. J Exp Med (1974) 2.45
Silicon nanowire-based solar cells on glass: synthesis, optical properties, and cell parameters. Nano Lett (2009) 2.41
Quantitative fecal indium 111-labeled leukocyte excretion in the assessment of disease in Crohn's disease. Gastroenterology (1983) 2.37
Low density lipoprotein and very low density lipoprotein are selectively bound by aggregated C-reactive protein. J Exp Med (1982) 2.33
Low-level increases in serum C-reactive protein are present in early osteoarthritis of the knee and predict progressive disease. Arthritis Rheum (1997) 2.31
Detection of Herpes simplex virus DNA by real-time PCR. J Clin Microbiol (2000) 2.29
Role of C3 in in vitro lymphocyte cooperation. Nature (1974) 2.27
Homozygous protein C deficiency manifested by massive venous thrombosis in the newborn. N Engl J Med (1984) 2.26
C-reactive protein and coronary heart disease: a critical review. J Intern Med (2008) 2.25
Reduction of diagnostic window by new fourth-generation human immunodeficiency virus screening assays. J Clin Microbiol (1998) 2.25
Role of complement in the induction of immunological responses. Transplant Rev (1976) 2.21
Analogues in other mammals and in fish of human plasma proteins, C-reactive protein and amyloid P component. Nature (1978) 2.18
Long-term survival in systemic amyloid A amyloidosis complicating Crohn's disease. Gastroenterology (1997) 2.18
C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction. J Exp Med (1999) 2.17
Isolation of human C-reactive protein and serum amyloid P component. J Immunol Methods (1982) 2.15
Serum amyloid-A protein concentration in inflammatory diseases and its relationship to the incidence of reactive systemic amyloidosis. Lancet (1982) 2.10
Amyloidosis. Histopathology (1994) 2.10
Isolation of amyloid P component (protein AP) from normal serum as a calcium-dependent binding protein. Lancet (1977) 2.09
Binding of serum amyloid P-component (SAP) by amyloid fibrils. Clin Exp Immunol (1979) 2.08
Measurement of serum C-reactive protein concentration in myocardial ischaemia and infarction. Br Heart J (1982) 2.07
Structure of pentameric human serum amyloid P component. Nature (1994) 2.07
Isolation of serum amyloid P-component (protein SAP) in the mouse. Immunology (1979) 2.07
Phylogenetic aspects of C-reactive protein and related proteins. Ann N Y Acad Sci (1982) 2.03
Conformational studies of poly-L-alanine in water. Biopolymers (1968) 2.02
Position-dependent accommodative shift of retropupillary fixated iris-claw lenses. Graefes Arch Clin Exp Ophthalmol (2012) 2.00
Temporary depletion of complement component C3 or genetic deficiency of C1q significantly delays onset of scrapie. Nat Med (2001) 1.99
Isolation of C-reactive protein by affinity chromatography. Clin Exp Immunol (1977) 1.97
C-reactive protein and cardiovascular disease: new insights from an old molecule. QJM (2003) 1.93
Risk factors for coronary heart disease and acute-phase proteins. A population-based study. Eur Heart J (1999) 1.87
Three dimensional structure of human C-reactive protein. Nat Struct Biol (1996) 1.87
Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis. Proc Natl Acad Sci U S A (1995) 1.83
The interfascicular nerve-grafting of the median and ulnar nerves. J Bone Joint Surg Am (1972) 1.82
Invasion of respiratory epithelial cells by Burkholderia (Pseudomonas) cepacia. Infect Immun (1996) 1.82
C-reactive protein, insulin resistance, central obesity, and coronary heart disease risk in Indian Asians from the United Kingdom compared with European whites. Circulation (2001) 1.81
Interleukin 6 influences germinal center development and antibody production via a contribution of C3 complement component. J Exp Med (1998) 1.78
A novel variant of transthyretin, 59Thr-->Lys, associated with autosomal dominant cardiac amyloidosis in an Italian family. Circulation (1995) 1.77
Pentameric and decameric structures in solution of serum amyloid P component by X-ray and neutron scattering and molecular modelling analyses. J Mol Biol (1997) 1.77
Pilonidal sinus disease. J Visc Surg (2013) 1.76
Value of serum C-reactive protein measurement in the investigation of fever in systemic lupus erythematosus. Ann Rheum Dis (1980) 1.76
Hereditary nephropathic systemic amyloidosis caused by a novel variant apolipoprotein A-I. Kidney Int (1998) 1.71
Amyloid P component is located on elastic fibre microfibrils in normal human tissue. Nature (1981) 1.70
The protofilament substructure of amyloid fibrils. J Mol Biol (2000) 1.69
Isolation and characterization of C-reactive protein and serum amyloid P component in the rat. Immunology (1982) 1.67
Persistence of pedicle blood flow up to 10 years after free musculocutaneous tissue transfer. Plast Reconstr Surg (1998) 1.67
Biology of serum amyloid P component. Ann N Y Acad Sci (1982) 1.65
On estimating recessive frequencies from truncated samples. Biometrics (1967) 1.62
Diagnostic radionuclide imaging of amyloid: biological targeting by circulating human serum amyloid P component. Lancet (1988) 1.61
C-reactive protein in SLE. Clin Rheum Dis (1982) 1.61
Insulin as an amyloid-fibril protein at sites of repeated insulin injections in a diabetic patient. Diabetologia (1988) 1.60
Matrix-assisted laser desorption/ionisation time-of-flight (MALDI-TOF) mass spectrometry as a tool for rapid diagnosis of potentially toxigenic Corynebacterium species in the laboratory management of diphtheria-associated bacteria. Euro Surveill (2010) 1.60
Right colonic involvement is associated with severe forms of ischemic colitis and occurs frequently in patients with chronic renal failure requiring hemodialysis. Am J Gastroenterol (2000) 1.59
Neonatal urinary uric acid/creatinine [correction of ceratinine] ratio as an additional marker of perinatal asphyxia. Eur J Pediatr (1995) 1.59
Cystic retroperitoneal lymphangiomas in adults. Eur J Surg Oncol (1997) 1.59
Preprocedural inflammatory markers do not predict restenosis after successful coronary stenting. Am Heart J (2004) 1.59
Amyloid P-component is a constituent of normal human glomerular basement membrane. J Exp Med (1980) 1.57
Amyloid deposition is delayed in mice with targeted deletion of the serum amyloid P component gene. Nat Med (1997) 1.56
Stability of the Astronomical Frequencies Over the Earth's History for Paleoclimate Studies. Science (1992) 1.54
Fibronectin and C4-binding protein are selectively bound by aggregated amyloid P component. J Exp Med (1981) 1.53
The purification of papain by affinity chromatography. Eur J Biochem (1970) 1.52
Preterm infants with low immunoglobulin G levels have increased risk of neonatal sepsis but do not benefit from prophylactic immunoglobulin G. J Pediatr (2000) 1.51
High tie versus low tie vascular ligation of the inferior mesenteric artery in colorectal cancer surgery: impact on the gain in colon length and implications on the feasibility of anastomoses. Dis Colon Rectum (2012) 1.51
Studies in vivo of cobra factor and murine C3. Immunology (1975) 1.49
Hormone binding globulins undergo serpin conformational change in inflammation. Nature (1988) 1.47
Role of serum amyloid P component in bacterial infection: protection of the host or protection of the pathogen. Proc Natl Acad Sci U S A (2000) 1.47
Malignant degeneration in Madelung's disease (benign lipomatosis of the neck): case report. Br J Plast Surg (1983) 1.46
Curative hepatorenal transplantation in systemic amyloidosis caused by the Glu526Val fibrinogen alpha-chain variant in an English family. QJM (2000) 1.45
A case-control study of risk factors for intraoperative suprachoroidal expulsive hemorrhage. Ophthalmology (1991) 1.45
Differing acute phase responses in Crohn's disease and ulcerative colitis. Gut (1986) 1.44
Hepatitis delta: on soft paws across Germany. Infection (2012) 1.43
Giant and reversible extrinsic magnetocaloric effects in La0.7Ca0.3MnO3 films due to strain. Nat Mater (2012) 1.43
Imaging of haemodialysis-associated amyloidosis with 123I-serum amyloid P component. Lancet (1991) 1.42